Kiora Pharmaceuticals Inc

7EY

Company Profile

  • Business description

    Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

  • Contact

    332 Encinitas Boulevard
    Suite 102
    EncinitasCA92024
    USA

    T: +1 858 224-9600

    https://www.kiorapharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    12

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,771.103.90-0.04%
CAC 407,742.2457.560.75%
DAX 4023,699.12182.890.78%
Dow JONES (US)42,515.09317.300.75%
FTSE 1008,875.2224.590.28%
HKSE24,007.2253.77-0.22%
NASDAQ19,701.21294.391.52%
Nikkei 22538,522.20210.870.55%
NZX 50 Index12,679.2210.91-0.09%
S&P 5006,033.1156.140.94%
S&P/ASX 2008,539.608.80-0.10%
SSE Composite Index3,382.146.59-0.19%

Market Movers